Patents by Inventor Edward A. Collins

Edward A. Collins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED GLYCOPROTEINS
    Publication number: 20170247426
    Abstract: Sulfated glycoproteins, and methods of making and using such sulfated glycoproteins, are described.
    Type: Application
    Filed: April 10, 2017
    Publication date: August 31, 2017
    Inventors: Dorota A. Bulik, Carlos J. Bosques, Brian Edward Collins, Maurice Gaston Hains, Nathaniel J. Washburn, James Meador, Sean Smith, Naveen Bhatnagar
  • METHODS OF CELL CULTURE
    Publication number: 20170233782
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using ammonium and/or lysine, are described.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 17, 2017
    Inventors: Brian Edward Collins, Holly Prentice, Brett Belongia, Rasheed Tijani
  • Methods related to denosumab
    Patent number: 9695244
    Abstract: The present invention relates to the characterization and production of denosumab.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: July 4, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Methods of cell culture
    Patent number: 9677105
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using ammonium and/or lysine, are described.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 13, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Brian Edward Collins, Holly Prentice, Brett Belongia, Rasheed Tijani
  • METHODS RELATED TO BIOLOGICS
    Publication number: 20170152319
    Abstract: The present invention relates to the characterization and production of biosimilars.
    Type: Application
    Filed: September 1, 2016
    Publication date: June 1, 2017
    Inventors: Brian Edward Collins, Joseph Glajch, John Robblee
  • Modified glycoproteins
    Patent number: 9650433
    Abstract: Sulfated glycoproteins, and methods of making and using such sulfated glycoproteins, are described.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: May 16, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Dorota A. Bulik, Carlos J. Bosques, Brian Edward Collins, Maurice Gaston Hains, Nathaniel J. Washburn, James Meador, Sean Smith, Naveen Bhatnagar
  • METHODS RELATED TO BIOLOGICS
    Publication number: 20170074890
    Abstract: The present invention relates to the characterization and production of biologics.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 16, 2017
    Inventors: Brian Edward Collins, Joseph Glajch, John Robblee
  • DEFINED GLYCOPROTEIN PRODUCTS AND RELATED METHODS
    Publication number: 20160097074
    Abstract: The invention provides methods, databases and systems for making glycoprotein products having defined properties.
    Type: Application
    Filed: October 14, 2015
    Publication date: April 7, 2016
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Brian Edward Collins, Carlos J. Bosques, Lakshmanan Thiruneelakantapillai, Dorota A. Bulik, Ian C. Parsons, Zachary Shriver, Rajeev Chillakuru, Ganesh Kaundinya
  • N-ACETYLHEXOSAMINE-CONTAINING N-GLYCANS IN GLYCOPROTEIN PRODUCTS
    Publication number: 20160060675
    Abstract: The present invention provides methods of evaluating a glycoprotein preparation for the absence, presence or amount of an N-acetylhexosamine glycan, e.g., an N-acetylglucosamine glycan.
    Type: Application
    Filed: September 9, 2015
    Publication date: March 3, 2016
    Inventors: Nathaniel Washburn, Enrique Arevalo, Kevin Millea, Carlos J. Bosques, Jay Duffner, Brian Edward Collins
  • Footwear with orthotic midsole
    Patent number: 9259050
    Abstract: Footwear is provided having a midsole platform, a full length insole and a orthotic midsole in the form of an orthotic shell received between the midsole platform and the insole. The orthotic shell has a heel portion to support a heel of a foot of a wearer and a forefoot portion to support a forefoot of the wearer at least in a region behind and near metatarsal heads of the foot. The orthotic shell is shaped to partially cup the heel and support the forefoot in one of a plurality of determined orientations. The footwear may further include a plurality of support plugs to support the orthotic shell in one of the determined orientations and a shank coupled to the midsole platform to increase torsional rigidity of the footwear with respect to a longitudinal length thereof. Methods of making footwear are also provided.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: February 16, 2016
    Assignee: Superfeet Worldwide, Inc.
    Inventors: Christopher E. Smith, Jeff Gray, Edward Collins, II, Peter Daley
  • METHODS RELATED TO DENOSUMAB
    Publication number: 20150246974
    Abstract: The present invention relates to the characterization and production of denosumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: September 3, 2015
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • METHODS OF EVALUATING AND MAKING BIOLOGICS
    Publication number: 20150204884
    Abstract: Methods of making and evaluating antibody biological therapeutics (biosimilars) for adalimumab, rituximab and panitumumab are disclosed.
    Type: Application
    Filed: May 31, 2013
    Publication date: July 23, 2015
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • METHODS RELATED TO ADALIMUMAB
    Publication number: 20150158943
    Abstract: Production and bioanalytical characterization of determinative parameters of adalimumab is presented.
    Type: Application
    Filed: May 31, 2013
    Publication date: June 11, 2015
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • METHODS RELATED TO PANITUMUMAB
    Publication number: 20150152184
    Abstract: The present invention relates to the characterization and production of panitumumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: June 4, 2015
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • METHODS RELATED TO BEVACIZUMAB
    Publication number: 20150147317
    Abstract: The present invention relates to the characterization and production of bevacizumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 28, 2015
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • METHODS RELATED TO RITUXIMAB
    Publication number: 20150141620
    Abstract: The present invention relates to the characterization and production of rituximab.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 21, 2015
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • METHODS RELATED TO OMALIZUMAB
    Publication number: 20150140608
    Abstract: The present invention relates to the characterization and production of omalizumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 21, 2015
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Characterization of N-glycans using exoglycosidases
    Patent number: 9029081
    Abstract: The present disclosure provides methods for analyzing structure and/or composition of N-glycans. Such methods often involve digestion of N-glycans with multiple exoglycosidases. In some embodiments, N-glycans are digested with multiple exoglycosidases simultaneously. In some embodiments, N-glycans are digested with multiple exoglycosidases sequentially. In some embodiments, methods in accordance with the present disclosure involve comparison of cleavage products of N-glycans that have been digested with multiple exoglycosidases simultaneously to N-glycans that have been digested with multiple exoglycosidases sequentially.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: May 12, 2015
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Ian Christopher Parsons, Dorota A. Bulik, Carlos J. Bosques, Lakshmanan Thiruneelakantapillai, Brian Edward Collins
  • METHODS RELATED TO ALEMTUZUMAB
    Publication number: 20150125848
    Abstract: The present invention relates to the characterization and production of alemtuzumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 7, 2015
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • METHODS RELATED TO TRASTUZUMAB
    Publication number: 20150104444
    Abstract: The present invention relates to the characterization and production of trastuzumab. The present disclosure provides, in part, methods for evaluating, identifying, and/or producing (e.g., manufacturing) trastuzumab. In some instances, methods herein allow highly resolved evaluation of trastuzumab useful for, inter alia, manufacturing trastuzumab, characterizing trastuzumab, identifying and/or confirming trastuzumab, monitoring the structure of trastuzumab, comparing trastuzumab preparations made over time or made under different conditions, and/or controlling the structure of trastuzumab.
    Type: Application
    Filed: May 31, 2013
    Publication date: April 16, 2015
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques